cancer
Specialists in cancerous diseases considered immunotherapy as the "first line of defense" in lung cancer, as it contributed to the long-term life expectancy of cancer patients, and according to a recent study, 18% of patients lived three years or more, explaining that this type constitutes a shift Quality in the treatment of a number of cancerous diseases, such as lung, bladder and skin cancer, especially as it stops the effect of the cancerous tumor on the immune system of the body, which helps the latter in attacking and fighting cancerous cells.
The director of the medical sector for oncology in the Middle East at the company "MCD", Dr. Ahmed Yousry, confirmed that the series of awareness workshops organized by the company aims to raise awareness of the latest innovations to treat cancer patients and improve their lives, and work with media professionals to publish accurate and useful information To the public.
The awareness workshops discussed a number of topics on current scientific developments, available cancer treatments and current gaps, immunotherapy and new developments related to its future use, the purpose of its medical experiments, and identifying which patients will benefit most from this treatment.
This came during a series of awareness-raising workshops organized by MSD (MCD), a healthcare professional, recently on the sidelines of the 2016 European Society of Medical Oncology (ESMO) annual conference in Copenhagen, Denmark.
In detail, the consultant of the Hematology and Oncology Consultant, the president of the Society of Oncologists in Jordan, Sanaa Al-Sukhun, said: “The price of immunotherapy is a great challenge for the whole world, compared to its benefit that has succeeded in overcoming many tumors that are difficult to deal with chemical and biological treatments, but with the passage of time its price will improve. Noticeable as was the case with chemotherapy, which appeared expensive in its beginning and improved over time.
For his part, the head of the Cancer Research Department at the Faculty of Medicine at Cairo University, Dr. Yasser Abdel-Qader, stated that “the physical barrier must be overcome in front of the patient''s access to immunotherapy, which is the first line of defense in lung cancer, and several cases have responded to this treatment in the long run. And that after I had a specific examination. ”
He pointed out that recovery from cancer is not impossible, and the presence of a new treatment such as immunotherapy has increased the chances of recovery, or even complete control of the disease.
While the head of the oncology department at the oncology center at King Faisal Specialist Hospital, deputy chairman of the Saudi Oncology Society, Dr. Shawqi Bazarbashi, mentioned that immunotherapy is very expensive, and it is one of the most expensive treatments in the market, and there is no study in the region about linking the price of the drug compared to its therapeutic benefit. .
He added that the methods of treatment for cancer diseases are many, and depend on several factors, the most prominent of which are the type, stage and location of cancer, and are distributed between surgical or radiotherapy or drug therapy (chemical, hormonal, biological, multi-immune), or topical treatment with burning, or milling, and immunotherapy is a hope for some types Cancer, but specialists should work together to work together to reach greater results on these treatments.
Dr. Abdullah Khalaf Al-Tuwairqi, director of the Consultative Oncology Fellowship Program at the Comprehensive Center for Oncology in the King Fahd Medical City in Riyadh, said that there are studies that demonstrated that immunotherapy contributed to the high rate of cancer patient’s long-term life, as 18% of patients lived three years Or more, according to a recent study.
He pointed out that studies of immunotherapy are divided into three degrees, the last degree of which proves the effectiveness of treatment or not, and there are studies of immunotherapy in a large number of cancerous diseases, including brain cancer, blood cancer, colon cancer and breast cancer, indicating that immunotherapy is old and its developments were slow except It has finally accelerated, and new immunomodulators are still being researched.
The doctor who specializes in cancerous diseases at the Ministry of Higher Education and Scientific Research and the Hawler University Medical College and the College of Medicine in the Kurdistan Region of Iraq, Dr. Luqman Suleiman, examined the tests performed to diagnose cancer, determine the quality of treatment, the importance of information collection and accurate diagnosis to determine the appropriate medicine for each disease.
